Holen Sie sich die Stockscreener-App
0.1902
8.69%
0.0152
Handel nachbörslich:
.21
0.0198
+10.41%
Schlusskurs vom Vortag:
$0.175
Offen:
$0.177
24-Stunden-Volumen:
13.94M
Relative Volume:
1.28
Marktkapitalisierung:
$12.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+18.88%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.1625
$0.194
1-Wochen-Bereich:
$0.15
$0.194
52-Wochen-Spanne:
$0.1159
$2.22
Profusa Inc Stock (PFSA) Company Profile
Firmenname
Profusa Inc
Sektor
Branche
Telefon
212-494-9022
Adresse
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Vergleichen Sie PFSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.1902 | 11.49M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
125.29 | 219.65B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.57 | 146.79B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
365.95 | 140.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.97 | 130.80B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.98 | 49.16B | 5.88B | 1.34B | 799.60M | 2.3489 |
Profusa Inc Aktie (PFSA) Neueste Nachrichten
Q&A: Real-time digital healthcare for 2026 - Digital Journal
Top investors say TSS Inc (TSSI) ticks everything they need - Setenews
Profusa to Present Late Breaking U.S. Based Clinical Trial Update at Paris Vascular Insights 2025 - MarketScreener
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025 - The Manila Times
Profusa (Nasdaq: PFSA) to Share U.S. Lumee PAD Trial Update at PVI 2025 conference - Stock Titan
Profusa (PFSA) Competitors and Alternatives 2025 - MarketBeat
Profusa (PFSA) Stock Forecast and Price Target 2025 - MarketBeat
Profusa, Inc.Common Stock (NQ: PFSA - Markets Financial Content
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Profusa, Inc. (PFSA) -10.7% in Normal Trading: Decline Amid Recent Financial Update - Stocks Telegraph
Profusa raises USD 12M in gross proceeds from convertible PIPE note - Medical Buyer
Profusa Announces Q3 Highlights and Strategic Merger - TipRanks
Profusa, Inc. Announces Third Quarter 2025 Financial Results and Business Highlights - TradingView
Profusa (PFSA) 10K Form and SEC Filings 2025 - MarketBeat
Profusa Announces Third Quarter Business and Financial Highlights - The Manila Times
Profusa, Inc. SEC 10-Q Report - TradingView
[10-Q] Profusa, Inc. Quarterly Earnings Report | PFSA SEC FilingForm 10-Q - Stock Titan
Profusa, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
PFSA News Today | Why did Profusa stock go up today? - MarketBeat
Profusa (PFSA) Stock Price, News & Analysis - MarketBeat
Is Profusa Inc (PFSA) positioned for future growth? - Setenews
Profusa Delays Filing of Quarterly Report - MSN
[NT 10-Q] Profusa, Inc. SEC Filing - Stock Titan
[SCHEDULE 13G/A] Profusa, Inc. SEC Filing - Stock Titan
What is Profusa Inc (PFSA) Stock Return on Shareholders’ Capital? - Setenews
Profusa invests additional $1 million in digital treasury assets - MSN
Profusa, Inc. (PFSA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Profusa Inc (PFSA) looking to reclaim success with recent performance - setenews.com
Profusa, Inc. (PFSA) stock price, news, quote and history - Yahoo! Finance UK
[8-K] Profusa, Inc. Reports Material Event | PFSA SEC FilingForm 8-K - Stock Titan
Profusa outlines EU launch of tissue oxygen monitoring in 2026 - Investing.com India
Profusa outlines revenue plan, targets EU commercial launch of Lumee in early Q2 2026 - MSN
Profusa outlines EU launch of tissue oxygen monitoring in 2026 By Investing.com - Investing.com South Africa
Profusa Unveils Strategic Plan for Revenue Growth - TipRanks
Profusa, Inc. Outlines Path to $250 Million Revenue by 2030 - TradingView
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches - The Manila Times
Profusa Outlines Potential Path to $250 Million Revenue by - GlobeNewswire
Profusa (PFSA) Stock Skyrockets 36% on Milestone News – Can This Biotech Sensor Play Rebound? - ts2.tech
Why Profusa (PFSA) Stock Soared 36% After Hours? - Benzinga
[424B3] Profusa, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Profusa completes manufacturing milestones ahead of 2026 product launch - Investing.com India
Profusa completes manufacturing milestones ahead of 2026 product launch By Investing.com - Investing.com Nigeria
Profusa IncOn track to provide inventory in Q1 2026 - MarketScreener
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026 - GlobeNewswire
Profusa Invests $1 Million in Digital Treasury Assets - MSN
Profusa Unveils Strategic Focus in Investor Update - MSN
Profusa expands European footprint for Lumee Oxygen platform - Investing.com India
Profusa expands European footprint for Lumee Oxygen platform By Investing.com - Investing.com Australia
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe - The Manila Times
Profusa expands sales footprint with new distributor for Lumee Oxygen platform in Europe - MarketScreener
Finanzdaten der Profusa Inc-Aktie (PFSA)
Es liegen keine Finanzdaten für Profusa Inc (PFSA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):